派罗欣联合利巴韦林在慢性丙肝治疗中的疗效和安全性

The Efficacy and Safety of Pegasys Combined with Ribavivin in the Treatment of Chronic Hepatitis C

目的探讨派罗欣联合利巴韦林在慢性丙肝治疗中的疗效和安全性。方法选取2015年1月～2017年1月盘锦市传染病医院收治的72例慢性丙肝患者，依据硬币法分为两组，各36例。对照组采取甘乐能与利巴韦林疗法，观察组则使用派罗欣与利巴韦林进行治疗。比较两组的治疗效果和不良反应。结果观察组持续应答率为91．7％，比对照组的72．2％更高，差异有统计学意义（P〈0．05）。两组不良反应发生率比较，差异无统计学意义（P〉0．05）。结论慢性丙肝患者使用派罗欣联合利巴韦林进行治疗临床效果确切，且具有良好的安全性，值得临床推广。

Objective The aim of the study is to investigate the efficacy and safety of pegasys combined with ribavivin in the treatment of chronic hepatitis C. Methods A total of 72 patients with chronic hepatitis C were recruited in Panjin City Hospital for Infectious Disease from January, 2015 to January, 2017. Based on coin grouping, all patients were randomly divided into observation group and control group （n=36 each group）. The patients in observation group were treated with pegasys combined with ribavirin, and the patients in control group were treated with interferon alpha 2b and ribavirin, respectively. The therapy effect and adverse reaction were compared between two groups. Results The sustained response rate in observation group was 91 .7%, and was significantly higher than 72.2% in control group （P〈0.05）. There was no significant difference in adverse reaction rate between two groups （P〉0.05）. Conclusion The pegasys combined with ribavivin has accuracy curative effect in the treatment of chronic hepatitis C, and is safe for the patients, deserving to extensive application.